SGLT-2 inhibitors and GLP-1 receptor agonists in primary care pharmacotherapy of type 2 diabetes in people living with HIV versus HIV-negative controls: Findings from a multicenter study in Germany
PLWH and T2D in primary care received similar evidence-based therapies as controls, however, prescription rates in participants with CV disease were relatively low. Future studies with a larger sample size and longitudinal follow-up are needed to confirm the present findings.
Authors
- Renate Schlottmann
- Alanna Ebigbo (ORCID: https://orcid.org/0000-0001-7765-035X)
- Anja Potthoff (ORCID: https://orcid.org/0000-0001-5323-1281)
- Bruce Kaup
- Sandeep Nambiar
- H. Nonseid-Jansen
- W.A. Jansen
- L. Hilgefort
- A. Skaletz-Rorowski
- W.E. Schmidt
- D.R. Quast
Institutions
- St. Josef-Hospital (DE)
- Katholisches Klinikum Bochum (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Primary care diabetes
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1016/j.pcd.2026.01.005
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00